Severity
Moderate
FDA Drug recall · Reported November 21, 2018
Failed Impurities/Degradation Specifications; out-of-specification results for impurities obtained during routine stability testing
Teva Pharmaceuticals USA recalled Alprostadil Injection USP 500 micrograms/mL 1 mL single use vial, 5 vials per carton, Rx … - a moderate-severity action.
Alprostadil Injection USP 500 micrograms/mL 1 mL single use vial, 5 vials per carton, Rx … was recalled by Teva Pharmaceuticals USA in November 21, 2018. Reason: Failed Impurities/Degradation Specifications; out-of-specification results for impurities obtained during rou…. Check the official notice for the remedy. Verify recall #D-0244-2019 with the FDA Drug before acting.
The recall
Teva Pharmaceuticals USA issued this moderate-severity FDA Drug recall-Failed Impurities/Degradation Specifications; out-of-specification results for impurities obtained during rou….
Sourced from official FDA Drug enforcement records. Verify recall #D-0244-2019 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0244-2019) was formally reported on November 21, 2018, with the manufacturer initiating the action on September 27, 2018. It is classified under Moderate severity (Class II), with a current status of Terminated. Teva Pharmaceuticals USA is listed as the recalling firm, operating out of North Wales, PA. Federal records list the affected scope as 1,362 vials.
The documented reason for this recall is: Failed Impurities/Degradation Specifications; out-of-specification results for impurities obtained during routine stability testing Distribution data in the federal record shows the product reached: Product was distributed throughout the United States, including Hawaii and Puerto Rico.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
1,362 vials
Related Recalls
6
5 from same agency
Alprostadil Injection USP 500 micrograms/mL 1 mL single use vial, 5 vials per carton, Rx only, TEVA Pharmaceuticals USA, Inc., North Wales, PA --- NDC 0703-1501-02
Failed Impurities/Degradation Specifications; out-of-specification results for impurities obtained during routine stability testing
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-0244-2019 |
| Date reported | November 21, 2018 |
| Date initiated | September 27, 2018 |
| Recalling firm | Teva Pharmaceuticals USA |
| Firm location | North Wales, PA |
| Affected scope | 1,362 vials |
| Distribution | Product was distributed throughout the United States, including Hawaii and Puerto Rico. |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported November 21, 2018. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.